TCGA-DK-A3X2-01A-11R-A22U-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 17.96977661
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.640
- G2M_CHECKPOINT+0.620
- MYC_TARGETS_V2+0.540
- MYC_TARGETS_V1+0.520
- MITOTIC_SPINDLE+0.480
- OXIDATIVE_PHOSPHORYLATION+0.460
- DNA_REPAIR+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.300
- MTORC1_SIGNALING+0.270
- SPERMATOGENESIS+0.260
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.610
- ANGIOGENESIS-0.580
- ALLOGRAFT_REJECTION-0.530
- INFLAMMATORY_RESPONSE-0.490
- COAGULATION-0.480
- TNFA_SIGNALING_VIA_NFKB-0.480
- KRAS_SIGNALING_UP-0.450
- IL6_JAK_STAT3_SIGNALING-0.430
- COMPLEMENT-0.410
- INTERFERON_GAMMA_RESPONSE-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 64935b9c-623d-40d4-bd89-f2af006b1f92 | — | — | 0.950 |
| 2 | TCGA-GC-A4ZW-01A-11R-A26T-07 | — | — | 0.936 |
| 3 | MBCproject_0227_T2_RNA | — | B | 0.934 |
| 4 | TCGA-51-4080-01A-01R-1100-07 | — | cohortSQ2 | 0.932 |
| 5 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.929 |
| 6 | TCGA-43-6143-01A-11R-1820-07 | — | cohortMD1 | 0.924 |
| 7 | TCGA-60-2719-01A-01R-0851-07 | — | cohortSQ1 | 0.923 |
| 8 | ERR2208894 | — | — | 0.922 |
| 9 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.921 |
| 10 | BS_YBJBSRHV | Embryonal tumors | — | 0.920 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.640 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.620 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.520 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.480 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |